Literature DB >> 10447009

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors.

J M Hershman1.   

Abstract

There is abundant evidence that human chorionic gonadotropin (hCG) is a weak thyrotropin (TSH) agonist. In FRTL-5 rat thyroid cells, hCG increases cyclic adenosine monophosphate (cAMP), iodide transport, and cell growth. hCG has thyroid-stimulating activity in bioassays in mice and in clinical studies in man. In cultured cells transfected with the human TSH receptor, hCG increases generation of cAMP. Molecular variants of hCG with increased thyrotropic potency include basic molecules with reduced sialic acid content, truncated molecules lacking the C-terminal tail, or molecules in which the 47-48 peptide bond in the beta-subunit loop is nicked. In normal pregnancy, when hCG levels are highest at 10 to 12 weeks gestation, there is suppression of serum TSH levels, presumably due to slight increases in free thyroxine (T4) concentration. In twin pregnancies, hCG levels tend to be higher and suppressed TSH levels are more frequent. Hyperemesis gravidarum, defined as severe vomiting in early pregnancy that causes 5% weight loss and ketonuria, is usually associated with increased hCG concentration. A high proportion of patients with hyperemesis gravidarum, about one-third to two-thirds in different series, have evidence of increased thyroid function. Only a small proportion of these patients have clinical hyperthyroidism, termed gestational thyrotoxicosis. These patients probably secrete a variant of hCG with increased thyroid-stimulating activity. Trophoblastic tumors, hydatidiform mole, and choriocarcinoma often cause hyperthyroidism because they secrete very large amounts of hCG. When the serum hCG exceeds about 200 IU/mL, hyperthyroidism is likely to be found. There is a correlation between the biochemical severity of hyperthyroidism and the serum hCG in these patients. Removal of the mole or effective chemotherapy of the choriocarcinoma cures the hyperthyroidism. In conclusion, hCG has thyroid-stimulating activity that influences thyroid function early in pregnancy when hCG levels are high. Excessive hCG secretion may cause hyperthyroidism in patients with hyperemesis gravidarum or trophoblastic tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447009     DOI: 10.1089/thy.1999.9.653

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

Review 1.  Hyperemesis gravidarum: current concepts and management.

Authors:  N K Kuşcu; F Koyuncu
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

Review 2.  Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.

Authors:  Matthew James Reilley; Lance C Pagliaro
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

3.  Hyperthyroidism and pregnancy. An Italian Thyroid Association (AIT) and Italian Association of Clinical Endocrinologists (AME) joint statement for clinical practice.

Authors:  R Negro; P Beck-Peccoz; L Chiovato; P Garofalo; R Guglielmi; E Papini; M Tonacchera; F Vermiglio; P Vitti; M Zini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

4.  Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum.

Authors:  Alex Stagnaro-Green; Marcos Abalovich; Erik Alexander; Fereidoun Azizi; Jorge Mestman; Roberto Negro; Angelita Nixon; Elizabeth N Pearce; Offie P Soldin; Scott Sullivan; Wilmar Wiersinga
Journal:  Thyroid       Date:  2011-07-25       Impact factor: 6.568

5.  Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system.

Authors:  Joan C Lo; Scott A Rivkees; Malini Chandra; Joel R Gonzalez; James J Korelitz; Michael W Kuzniewicz
Journal:  Thyroid       Date:  2015-04-14       Impact factor: 6.568

Review 6.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 7.  Thyroid disorders in pregnancy.

Authors:  Alex Stagnaro-Green; Elizabeth Pearce
Journal:  Nat Rev Endocrinol       Date:  2012-09-25       Impact factor: 43.330

8.  Variability in thyroid-stimulating hormone suppression by human chorionic [corrected] gonadotropin during early pregnancy.

Authors:  James E Haddow; Monica R McClain; Geralyn Lambert-Messerlian; Glenn E Palomaki; Jacob A Canick; Jane Cleary-Goldman; Fergal D Malone; T Flint Porter; David A Nyberg; Peter Bernstein; Mary E D'Alton
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

9.  Case studies in hypertension: presentation with vaginal bleeding and hypertension.

Authors:  Joe Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-11       Impact factor: 3.738

Review 10.  The Effect of Thyrotropin-Releasing Hormone and Antithyroid Drugs on Fetal Thyroid Function.

Authors:  Nikolaos Vrachnis; Orestis Tsonis; Dionisios Vrachnis; Nikolaos Antonakopoulos; George Paltoglou; Stavroula Barbounaki; George Mastorakos; Minas Paschopoulos; Zoi Iliodromiti
Journal:  Children (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.